- Home
- NXL vs FEMY Comparison
NXL vs FEMY Comparison
Compare NXL & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- FEMY
- Stock Information
- Founded
- NXL 2010
- FEMY 2004
- Country
- NXL United States
- FEMY United States
- Employees
- NXL N/A
- FEMY N/A
- Industry
- NXL Medical Specialities
- FEMY Medical/Dental Instruments
- Sector
- NXL Health Care
- FEMY Health Care
- Exchange
- NXL Nasdaq
- FEMY Nasdaq
- Market Cap
- NXL 31.1M
- FEMY 34.3M
- IPO Year
- NXL 2022
- FEMY 2021
- Fundamental
- Price
- NXL $1.94
- FEMY $1.29
- Analyst Decision
- NXL Strong Buy
- FEMY Strong Buy
- Analyst Count
- NXL 1
- FEMY 2
- Target Price
- NXL $5.00
- FEMY $11.50
- AVG Volume (30 Days)
- NXL 123.3K
- FEMY 592.0K
- Earning Date
- NXL 03-14-2025
- FEMY 03-27-2025
- Dividend Yield
- NXL N/A
- FEMY N/A
- EPS Growth
- NXL N/A
- FEMY N/A
- EPS
- NXL N/A
- FEMY N/A
- Revenue
- NXL $168,721.00
- FEMY $1,629,108.00
- Revenue This Year
- NXL $175.37
- FEMY $550.60
- Revenue Next Year
- NXL $334.78
- FEMY $76.32
- P/E Ratio
- NXL N/A
- FEMY N/A
- Revenue Growth
- NXL 52.35
- FEMY 51.97
- 52 Week Low
- NXL $0.53
- FEMY $0.86
- 52 Week High
- NXL $4.49
- FEMY $1.84
- Technical
- Relative Strength Index (RSI)
- NXL 37.77
- FEMY 37.64
- Support Level
- NXL $2.16
- FEMY $1.25
- Resistance Level
- NXL $2.57
- FEMY $1.63
- Average True Range (ATR)
- NXL 0.22
- FEMY 0.17
- MACD
- NXL -0.00
- FEMY -0.03
- Stochastic Oscillator
- NXL 9.52
- FEMY 7.84
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.